NCT06295211Completed
Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
Source: ClinicalTrials.gov · Last updated 6 Mar 2024
Brief summary (registry, in English)
This is a retrospective, monocenter and non-interventional study. Data were retrospectively collected from all patients who completed the BV-Bs scheme in the time period between 1 September 2013 and 1 September 2023.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 32 (actual)
- First submitted
- 23 Feb 2024
- Start date
- 1 Sept 2013
- Primary completion date
- 1 Sept 2023
- Lead sponsor
- Federico II University
- Diseases
- Hodgkin lymphoma
- NCT number
- NCT06295211
What you commit to
- Study type: Observational
- Participants enrolled: 32
- From 1 Sept 2013 to the primary completion date, 1 Sept 2023
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- patients not fulfilling inclusion criteria
Who the study is looking for
- patients age between 18 years and 60 years;
- histological confirmation of CD30+ subtype cHL at first relapse or at refractory (patients who have failed to achieve complete remission at the end of treatment with 4-6 cycles of ABVD or who have progressed early during front-line treatment \[after 2 cycles of ABVD\] with interim FDG-PET/CT with Deauville scale score of 5 \[primary refractory patients\])
- treatment with at least 1 cycle of Bs and Bv at doses of 120 mg/m2 and 1.8 mg/kg, respectively
- metabolically active disease measurable at fluoro-desossi-glucose-positron emission tomography/computed tomography (FDG-PET/CT)
- EGOG performance status 0-2 (or 3, if due to illness).
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.